Regeneron is down 31.4% since the beginning of the year, and at $490.50 per share, it is trading 59.2% below its 52-week high of $1,202 from August 2024. Investors who bought $1,000 worth of ...

Through the deal, Regeneron says it aims to bolster its capabilities in genomics-driven drug discovery by integrating 23andMe's trove of over 15 million customer DNA profiles, collected via its ...

(Reuters) -Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking investor worries as U.S. regulators denied ...

This is systemic. Regeneron’s acquisition marks the end of an era in which data was collected under the illusion of control. From now on, it’s inherited. It’s monetized. It’s weaponized.